drugset / Trial / NCT04147416

A Study Evaluating the Efficacy and Safety of HSK3486 for Sedation

NCT04147416

Phase 2 Completed 39 enrolled Sichuan Haisco Pharmaceutical Group Co., Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-center, open-label, randomized, propofol-controlled phase II clinical trial.A total of ICU patients undergoing mechanical ventilation are intended to be enrolled and randomly assigned to HSK3486 group and propofol group in a 2:1 ratio.

Timeline

Start
2019-11-22
Primary completion
2020-05-31
Completion
2020-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cipepofol Small molecule 0.3 mg/kg Intravenous
Comparator Propofol Small molecule 1.5 mg/kg Intravenous

Indications

No indication recorded.